StockTipsArenaBeta

BUY Alivus Life Sciences Limited — Shrikant Chouhan, Kotak Securities

BUYAlivus Life Sciences Limited
Alivus Life Sciences share price target & all analyst calls

byShrikant Chouhan, Kotak SecuritiesHorizon: NA (inferred 1–3 months)30 Jun 2026via ET Now (Live)

Entry₹1,159.8Stated
Target₹1,315
Total upside +13.38% (call closed)
Stop lossNot given
Exit₹1,3154 Aug 2026, 12:08 pm
Target hit+13.38%0.00%upside left
Follow Shrikant Chouhan for new calls(42% target hit, 24 closed calls)Get alertsWatch ALIVUS for new buy/sell callsGet alertsSee 42 active Short-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 4 Aug 2026
1 supporting1 neutral0 opposing
Supports the BUY call (1)

Alivus Life Sciences reported its Q1FY27 results, showing highest-ever PAT with 31.8% YoY growth and margins at 25%. Revenue grew 6.4% YoY to Rs. 6,404 Mn, driven by the non-GPL business. EBITDA grew

BSE · Company Update·30 Jul · 4d ago

(opens in new tab)
Neutral / worth noting (1)

Alivus Life Sciences Ltd announced its unaudited financial results for the first quarter ended June 30, 2026. The results were approved by the Board of Directors and are available on the company's web

BSE · Board Meeting·30 Jul · 4d ago

(opens in new tab)
Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Alivus Life Sciences

All analyst calls on Alivus Life Sciences

More from Shrikant Chouhan, Kotak Securities

Every call and its outcome